Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
Shixue ChenZiwei HuangWangping JiaHaitao TaoSujie ZhangJunxun MaZhefeng LiuJinliang WangLijie WangPengfei CuiZhibo ZhangDi HuangZhaozhen WuXuan ZhengYi HuPublished in: Journal of hepatocellular carcinoma (2020)
Pretreatment LIPI combined with a dNLR ≥ 3 and/or LDH ≥ ULN is associated with poor outcomes in patients with aHCC treated with PD-1 inhibitors. Further validation in large, prospective studies are warranted.
Keyphrases